D-Index & Metrics Best Publications

Nadia Harbeck

Ludwig-Maximilians-Universität München
Germany

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 97 Citations 37,015 1,062 World Ranking 5571 National Ranking 284

Overview

What is she best known for?

The fields of study Nadia Harbeck is best known for:

Cancer
Breast cancer
Fulvestrant

A significant part of her Estrogen receptor research incorporates Progesterone receptor and Fulvestrant studies. Nadia Harbeck performs integrative study on Fulvestrant and Palbociclib in her works. Nadia Harbeck's looking at Metastasis as part of her Primary tumor and Intravasation and Metastasis study. Many of her studies on Internal medicine involve topics that are commonly interrelated, such as Consensus conference. Her research brings together the fields of Sentinel node and Cancer. Borrowing concepts from Radiation therapy, Nadia Harbeck weaves in ideas under Oncology. Nadia Harbeck carries out multidisciplinary research, doing studies in Radiation therapy and Adjuvant therapy. In her works, Nadia Harbeck performs multidisciplinary study on Adjuvant therapy and Neoadjuvant therapy. She carries out multidisciplinary research, doing studies in Breast cancer and Triple-negative breast cancer.

Her most cited work include:

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (737 citations)
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) (697 citations)
Triple-negative breast cancer—current status and future directions (504 citations)

What are the main themes of her work throughout her whole career to date

Her study on Internal medicine is mostly dedicated to connecting different topics, such as Consensus conference. She merges Cancer with Surgery in her research. With her scientific publications, her incorporates both Surgery and Cancer. Nadia Harbeck undertakes multidisciplinary investigations into Oncology and Chemotherapy in her work. In her research, she performs multidisciplinary study on Chemotherapy and Breast cancer. Her work blends Gynecology and Pathology studies together. Nadia Harbeck conducts interdisciplinary study in the fields of Pathology and Gynecology through her works. Her Adjuvant study frequently links to other fields, such as Oncology. In her works, she performs multidisciplinary study on Cancer research and Metastasis.

Nadia Harbeck most often published in these fields:

Internal medicine (87.80%)
Cancer (87.80%)
Breast cancer (75.61%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)

1852 Citations

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)

1822 Citations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)

1516 Citations

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)

1413 Citations

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés.
Journal of Clinical Oncology (2010)

1202 Citations

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2017)

937 Citations

Pembrolizumab for Early Triple-Negative Breast Cancer.

Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur.
The New England Journal of Medicine (2020)

926 Citations

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)

753 Citations

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

F. Cardoso;A. Costa;L. Norton;E. Senkus.
Annals of Oncology (2014)

752 Citations

Triple-negative breast cancer—current status and future directions